{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:5353365",
      "entity_text" : "CSC",
      "entity_type" : "simple_chemical"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:446013",
      "entity_text" : "FDA",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "A screen of U.S. Food and Drug Administration (FDA)-approved small molecules identified the anti-leprosy drug clofazimine as a preferential inhibitor of Cx46 mediated cell-cell communication and GBM CSC maintenance.",
  "reading_complete" : "2020-08-08T12:22:32Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T12:19:35Z",
  "trigger" : "mediated",
  "evidence" : [ "FDA)-approved small molecules identified the anti-leprosy drug clofazimine as a preferential inhibitor of Cx46-mediated cell-cell communication and GBM CSC" ],
  "pmc_id" : "6497083",
  "score" : 0
}